Analysis of Epidemiological Indicators of Pseudomonas Aeruginosa and Its Significance in Medical Practice

Patients with cystic fibrosis, burn injuries, immunodeficiency, cancer, chronic obstructive pulmonary disease (COPD), and serious infections needing ventilation, such COVID-19, can contract Pseudomonas aeruginosa (P. aeruginosa), a Gram-negative opportunistic bacteria. Additionally, P. aeruginosa is a model bacterium that is frequently utilized in various scientific fields. Rapid advancements have been made in the study of host-pathogen interaction, specifically host immune networks involving autophagy, inflammasome, non-coding RNAs, cGAS, etc., in addition to ongoing, intense efforts to comprehend bacterial pathogenesis of P. aeruginosa, including virulence factors (LPS, quorum sensing, two-component systems, six type secretion systems, outer membrane vesicles (OMVs), CRISPR-Cas and their regulation). Furthermore, we now have a better understanding of P. aeruginosa pathogenesis and host defense because to a number of technological advancements, including bioinformatics, metabolomics, scRNA-seq, nanoparticles, drug screening, and phage therapy. However, there is still much to learn about how P. aeruginosa and host immune responses interact, including drug resistance mechanisms caused by known or unknown bacterial virulence factors and mammalian cell signaling pathways. In order to screen and develop mechanism-tested novel drugs to treat intractable infections, particularly those caused by multi-drug resistant strains, new theoretical and practical platforms are required due to the widespread use of antibiotics and the slow development of effective antimicrobials. The analysis of this pathogen's characteristics has advanced into molecular and mechanistic details as well as dynamic and holistic perspectives thanks to advances in research instruments and technology. The current state of P. aeruginosa biophysical traits, behaviors, virulence factors, invasive regulators, and host defense patterns against its infection are all thoroughly reviewed and discussed here. These developments indicate new avenues for future research and contribute to the development of novel and/or alternative therapeutics to fight this clinically significant pathogen.